$SN

Barrocas Mark sold $88.8M of SN

Barrocas Mark (Chief Executive Officer) sold 500,000 shares of SharkNinja, Inc. (SN) at an average of $177.50 ($170.00–$185.00, $88.75M total) across 2 trades over 2026-08-05 to 2026-08-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Barrocas Mark
Published Aug 7, 2026, 10:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SN
Neutral
medium confidence
Mentioned
$SN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNNeutralLow
01

Why it matters

The filing reports the execution details of an open-market sale (500,000 shares, $88.75M total) and confirms the trades were under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity or correlate with any concurrent company news, but the 10b5-1 structure limits fundamental inference.

03

What to watch

Insider sales can be scheduled regardless of outlook; without accompanying changes in guidance, contracts, or results, the trading edge is limited.

Relevance 7/10Novelty 5/10Timing: Filed 2026-08-07 after sales executed 2026-08-05 to 2026-08-06.

Background

This is an SEC Form 4 insider transaction disclosure for SharkNinja, Inc. (SN) by CEO Mark Barrocas.

Company-level read

Ticker impact

$SNNeutralMedium confidence
Context

SharkNinja CEO Mark Barrocas sold 500,000 shares in open-market transactions totaling about $88.75M under a 10b5-1 plan.

Expected impact

Near-term impact likely limited; any reaction may fade unless accompanied by other company-specific news.

Evidence & confidence

Form 4 discloses transaction size and pricing range ($170 to $185) but does not provide new operational or financial information. 10b5-1 pre-arrangement typically dampens interpretive value.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale may be purely liquidity-driven under a pre-arranged 10b5-1 plan, so it should not be treated as a fresh bearish signal.

Key entities

  • SharkNinja, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Mark Barrocas

    CEO and director who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SNHighAI 8/10

Smith & Nephew merger talks with J&J orthopaedics unit collapse over CEO role, FT reports

Smith & Nephew's merger talks with Johnson & Johnson's orthopaedics unit collapsed over disagreement on the CEO role, according to the Financial Times. The deal would have valued the unit at up to $22 billion, nearly double Smith & Nephew's market cap. Both companies were aligned on financial terms but disagreed on leadership. Smith & Nephew's former CEO left in 2019 over pay demands.

$SNMed

UBS sees attractive risk/reward in three European medtech into Q3 results

UBS identifies Convatec, Smith & Nephew, and Sonova as attractive European medtech stocks ahead of Q3 results, citing revenue and earnings growth expectations. Convatec is expected to report 6% organic growth, Smith & Nephew may undergo a strategic review, and Sonova could raise guidance due to market growth and currency tailwinds. UBS provides price targets for each company.

$SNHighAI 8/10

Blowout Guidance Sends SharkNinja Shares Higher

SharkNinja (SN) reported Q2 2026 net sales of $1.77B (up 22.2% YoY) and adjusted net income of $178M (up 29%). The company raised full-year 2026 guidance, targeting up to 17% sales growth and $6.55 adjusted EPS. SN shares have risen 56% YTD, supported by institutional demand and strong fundamentals, including 3-year sales growth of 20% and EPS growth of 63.8%.

$SNMed

UBS raises SharkNinja stock price target to $219 on product expansion

UBS raised its price target for SharkNinja (NYSE:SN) to $219.10 from $147 and kept a Buy rating, citing Q2 results and faster product launches. The firm pointed to 13 new products year to date versus nine in the first eight months of 2025, plus plans for up to three new subcategories in 2026. SN trades at $187.68 and reported revenue of $1.77B (+22.2%) with adjusted EPS of $0.92.